Pure Biologics SA stock analysis
Pure Biologics SA (PQB) Stock Price & Analysis
PQB Stock Chart & Stats
- Day’s Range
- EUR 0.23 - EUR 0.23
- 52-Week Range
- EUR 0.22 - EUR 1.22
- Previous Close
- EUR 0.23
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- EUR 71.66M
- Enterprise Value
- EUR 31.74T
- Total Cash (Recent Filing)
- EUR 1.02M
- Total Debt (Recent Filing)
- EUR 14.40M
- Price to Earnings (P/E)
- ―
- Beta
- 0.12
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
PQB FAQ
What was Pure Biologics SA’s price range in the past 12 months?
What is Pure Biologics SA’s market cap?
When is Pure Biologics SA’s upcoming earnings report date?
Is Pure Biologics SA overvalued?
Does Pure Biologics SA pay dividends?
What is Pure Biologics SA’s EPS estimate?
How many shares outstanding does Pure Biologics SA have?
Which hedge fund is a major shareholder of Pure Biologics SA?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Pure Biologics SA
Pure Biologics Spólka Akcyjna operates as a biopharmaceutical enterprise, concentrating its efforts on the discovery and development of novel biological pharmaceuticals and targeted, non-systemic treatments. The company's key therapeutic interests span immuno-oncology, various autoimmune conditions, and rare diseases. Its capabilities encompass the entire process for antibodies and aptamers, from their initial creation and purification to detailed analysis and characterization. Additionally, Pure Biologics is skilled in the design, development, and rigorous validation of diagnostic and research assays, while also advancing technology platforms for the precise selection of active therapeutic molecules. A significant offering is PureApta, a adaptable platform engineered for the in vitro selection of modified aptamers, suitable for both medical treatment and diagnostic applications. The firm is also actively pursuing the development of localized therapies aimed at assisting individuals afflicted by neurological autoimmune disorders, including conditions like neuromyelitis optica and myasthenia gravis. Founded in 2010, Pure Biologics Spólka Akcyjna is headquartered in Wroclaw, Poland.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Filip Jelen
- Employees
- 7
- Website
- www.purebiologics.com
- Address
- Szczytnicka 11, Wroclaw, DS, 54-427, PL
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 3 | 6 | 13 |
| Technical Analysis | 1 | 6 | 3 |
| Moving Averages | 2 | 0 | 10 |

